DOI: 10.12890/2023_004216

Complications secondary to the use of SGLT2 inhibitors in oncological patients: a series of 5 cases

Authors

  • Luis Posado-Domínguez Medical Oncology Department, University Hospital of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain 0009-0005-4606-2316
  • Luis Figuero-Pérez Medical Oncology Department, University Hospital of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain 0000-0002-0906-5076
  • María Aranzazu Amores-Martin Medical Oncology Department, University Hospital of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
  • Pablo Reguera-Puertas Medical Oncology Department, University Hospital of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain 0000-0002-0847-5719
  • María Martín-Galache Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Pediatric Department, University Hospital of Salamanca, Salamanca, Spain
  • Edel Del Barco-Morillo Medical Oncology Department, University Hospital of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Faculty of Medicine, University of Salamanca, Salamanca, Spain 0000-0001-6443-0585
  • Emilio Fonseca-Sánchez Medical Oncology Department, University Hospital of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Faculty of Medicine, University of Salamanca, Salamanca, Spain

luisposado@usal.es

Keywords

iSGLT2, cancer, metabolic acidosis, sepsis

Abstract

Sodium-glucose cotransporter-2 (iSGLT2) inhibitors, which include dapagliflozin, canagliflozin and empagliflozin, are a class of drugs initially used in the oral treatment of diabetes, heart failure and renal failure. They target the reabsorption of glucose in the kidney. Although they bring benefit to patients with these conditions and in general produce few adverse effects, in some cases, iSGLT2 can cause serious adverse effects such as metabolic acidosis, and fungal or bacterial urinary infections. Oncology patients, who in general have a weak immune system and are usually treated with chemotherapy and/or immunotherapy, are more susceptible to this type of adverse events than other patients. For this reason, it is necessary to adequately select the patients eligible to receive this type of drug and evaluate the potential benefits for them. In this series of five cases, we present two cases of metabolic acidosis, two cases of bacterial urinary sepsis, and one case of fungal urinary sepsis that occurred in patients admitted to the Medical Oncology Department of the University Hospital of Salamanca in 2023.

View the entire article

Downloads

References

  1. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 2020;17:761-772.
  2. Dubrofsky L, Srivastava A, Cherney DZ. Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review. Can J Kidney Health Dis 2020;7:2054358120935701.
  3. Tsai WC, Hsu SP, Chiu YL, Yang JY, Pai MF, Ko MJ, et al. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open 2022;12:e060655.
  4. Zhang L, Tamilia M. Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor. CMAJ 2018;190:E766-E768.
  5. Esteban-Jiménez O, Navarro-Pemán C, Urieta-González L. Seguridad de los iSGLT-2. Revisión de las reacciones adversas notificadas a nivel nacional. Semergen 2018;44:23–29.
  6. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections [Internet]. U.S. Food and Drug Administration. FDA; 2023 [last accessed: November 6, 2023]. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious

Published

2023-12-06

Issue

Vol. 11 No. 1 (2024)

Categories

How to Cite

1.
Posado-Domínguez L, Figuero-Pérez L, Amores-Martin MA, Reguera-Puertas P, Martín-Galache M, Del Barco-Morillo E, et al. Complications secondary to the use of SGLT2 inhibitors in oncological patients: a series of 5 cases. EJCRIM [Internet]. 2023 Dec. 6 [cited 2026 Nov. 3];11(1). Available from: https://ejcrim.com/index.php/ejcrim/article/view/4216

Most read articles by the same author(s)